The Mini-Summit brought together experts in all aspects of HIV vaccinology, including those working with non-human primate models, virologists, clinical trialists, immunologists, epidemiologists, and statisticians. The goal was to determine the best way forward for evaluating Ad-HIV vectors based on an in-depth discussion about HIV vaccine platforms using recombinant Ad vectors.
The Mini-Summit included a focused discussion on questions pertaining to the impact of Ad5 vaccines on HIV acquisition, potential mechanisms involved, and how this informs future human clinical trials.
An archived webcast is available.
Last Updated September 26, 2013
Last Reviewed September 04, 2013